We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byΘυία Δράκος
Modified over 4 years ago
Patterns and Predictors of Chemotherapy Use for Resected Non-Small Cell Lung Cancer Ravi Rajaram, MD, MSc, Jennifer L. Paruch, MD, MS, Sanjay Mohanty, MD, MS, Jane L. Holl, MD, MPH, Karl Y. Bilimoria, MD, MS, Clifford Y. Ko, MD, MSHS, David P. Winchester, MD, Jyoti D. Patel, MD, Malcolm M. DeCamp, MD The Annals of Thoracic Surgery Volume 101, Issue 2, Pages (February 2016) DOI: /j.athoracsur Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Graph shows the proportion of patients with stage IB disease who received neoadjuvant chemotherapy (blue), adjuvant chemotherapy (green), or surgical resection only (orange) over time. The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Graph shows the proportion of patients with stage II to IIIA disease who received neoadjuvant chemotherapy (blue), adjuvant chemotherapy (green), or surgical resection only (orange) over time. The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
Elizabeth A. David, MD, David T
Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L
A Propensity-Matched Analysis of Wedge Resection and Stereotactic Body Radiotherapy for Early Stage Lung Cancer Jeffrey L. Port, MD, Bhupesh Parashar,
Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer
Thomas J. Birdas, MD, Richard P. M
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Comparison of Video-Assisted Thoracoscopic Surgery and Robotic Approaches for Clinical Stage I and Stage II Non-Small Cell Lung Cancer Using The Society.
Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival Elizabeth A. David, MD, Robert J. Canter,
The Society of Thoracic Surgeons Lung Cancer Resection Risk Model: Higher Quality Data and Superior Outcomes Felix G. Fernandez, MD, MS, Andrzej S. Kosinski,
Joshua E. Rosen, BASc, Hari B
Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer
Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis
Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B
Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.
Nirav S. Kapadia, MD, MS, Luca F. Valle, MD, Julie A
Oncologic Outcomes After Surgical Resection of Subcentimeter Non-Small Cell Lung Cancer Matthew J. Schuchert, MD, Arman Kilic, BS, Arjun Pennathur, MD,
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD
Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.
A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients Elizabeth A. David, MD, Stina W. Andersen, PhD,
© 2023 SlidePlayer.com Inc. All rights reserved.